Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Vertex, Pfizer And Others Disclose Trial Disruptions, Viatris Merger Delayed

Executive Summary

Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.

You may also be interested in...



Pfizer Q1: Headwinds And Tailwinds From COVID-19

The company reaffirmed 2020 sales and earnings financial guidance, highlighting the resiliency of the business amid a global pandemic, but Pfizer did highlight some potential business challenges.

For Pfizer, Vaccines and Vyndaqel In The Q1 Spotlight

Earnings preview: Pfizer's newly launched rare disease drug Vyndaqel and vaccines could be impacted by COVID-19. Investors will also be eager to hear more about the timeline for closing the Upjohn transaction.

Vir Advances HBV, Flu Programs While Focused On COVID-19

Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel